Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2195 (LINC02195)
- Target
- LINC02195
- Molecular classification
- Long non-coding RNA (lncRNA), Other (does not fit classic receptor/enzyme/transcription factor/ion channel categories)
01
Overview
Long intergenic non-protein coding RNA 2195 (LINC02195) is a nuclear and cytoplasmic long non-coding RNA implicated in immune regulation within the tumor microenvironment. It is highly expressed in certain immune-rich tissues such as the appendix, esophagus, lymph node, stomach, and thyroid, and notably overexpressed in head and neck squamous cell carcinoma (HNSCC) compared to normal tissue. Functionally, LINC02195 positively regulates major histocompatibility complex class I (MHC I, including HLA-A, -B, and -C), enhancing antigen processing and presentation pathways and is associated with increased infiltration of CD8^+^ and CD4^+^ T lymphocytes within tumors. High LINC02195 expression is linked to improved prognosis in HNSCC. Although not currently a direct drug target, LINC02195 represents a candidate prognostic biomarker and a putative future immunotherapeutic target due to its critical role in modulating the anti-tumor immune response.
- Other names
- LINC02195ENSG00000236481
02
Biological functions
Regulation of antigen processing and presentationImmune response modulation (especially via MHC I and II pathways)Modulation of T cell infiltration in the tumor microenvironment
03
Disease associations
Cancer (most prominently HNSCC; potentially others via similar mechanisms)
04
Biomarkers
High LINC02195 expression is a prognostic biomarker for favorable outcome in HNSCCHigh LINC02195 correlates with increased CD8^+^ and CD4^+^ T cell tumor infiltration
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2195 (LINC02195).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2195 (LINC02195).